Showing results (1741-1750 of 1,945) with videos related to

Sort By:
Pageof 195
Vaccine|April 10, 2016
Adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trialThomas Nørrelykke Nissen, Nina Marie Birk, Jesper Kjærgaard, et al.
Clinical Immunology (Orlando, Fla.)|December 24, 2022
The impact of BCG dose and revaccination on trained immunityPriya A Debisarun, Gizem Kilic, L Charlotte J de Bree, et al.
World Journal of Urology|January 22, 2021
Association between chronic kidney disease and COVID-19-related mortality in New YorkNihal E Mohamed, Emma K T Benn, Varuna Astha, et al.
Atherosclerosis|March 11, 2015
Does cellular sex matter? Dimorphic transcriptional differences between female and male endothelial cellsMario Lorenz, Janina Koschate, Katharina Kaufmann, et al.
Endocrine-Related Cancer|March 14, 2014
Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumoursV H M Tsang, T Dwight, D E Benn, et al.
The Journal of Allergy and Clinical Immunology|March 29, 2017
Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trialLisbeth Marianne Thøstesen, Lone Graff Stensballe, Gitte Thybo Pihl, et al.
Journal of Travel Medicine|August 29, 2024
Fatal journeys: causes of death in international travellers in South AmericaKasim Allel, Miguel M Cabada, Behzad Kiani, et al.
Journal of the International AIDS Society|February 15, 2021
Home-Based Intervention to Test and Start (HITS): a community-randomized controlled trial to increase HIV testing uptake among men in rural South AfricaFrank C Tanser, Hae-Young Kim, Thulile Mathenjwa, et al.
Journal of Innate Immunity|November 7, 2013
Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunityJohanneke Kleinnijenhuis, Jessica Quintin, Frank Preijers, et al.
The Patient|May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
Pageof 195